(Q38881996)

English

Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.

scientific article published on 13 April 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Jonas Abrahamsson

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

Elizabeth Bjørklund

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sanna Siitonen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Hanne Vibeke Marquart

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Gitte Wulff-Juergensen

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Tarja-Terttu Pelliniemi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Erik Forestier

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Kirsi Jahnukainen

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Birgitte Lausen

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Olafur G Jonsson

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Josefine Palle

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Bem Zeller

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Linda Fogelstrand

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

language of work or name

0 references

publication date

13 April 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

174

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

600-609

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

describes a project that uses

1 reference

based on heuristic

inferred from title

The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Tumor heterogeneity makes AML a "moving target" for detection of residual disease

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14093

21 January 2018

Identifiers

10.1111/BJH.14093

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27072379%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38881996&oldid=1877535739"